DK1492767T3 - Visse 1-(D-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazinforbindelser som inhibitorer af serinproteasefaktoren XA - Google Patents

Visse 1-(D-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazinforbindelser som inhibitorer af serinproteasefaktoren XA

Info

Publication number
DK1492767T3
DK1492767T3 DK03714138T DK03714138T DK1492767T3 DK 1492767 T3 DK1492767 T3 DK 1492767T3 DK 03714138 T DK03714138 T DK 03714138T DK 03714138 T DK03714138 T DK 03714138T DK 1492767 T3 DK1492767 T3 DK 1492767T3
Authority
DK
Denmark
Prior art keywords
inhibitors
cyclopropylglycinyl
piperidin
certain
serine protease
Prior art date
Application number
DK03714138T
Other languages
Danish (da)
English (en)
Inventor
Gary Lowell Engel
Michael Robert Wiley
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1492767T3 publication Critical patent/DK1492767T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK03714138T 2002-04-01 2003-03-24 Visse 1-(D-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazinforbindelser som inhibitorer af serinproteasefaktoren XA DK1492767T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36852302P 2002-04-01 2002-04-01

Publications (1)

Publication Number Publication Date
DK1492767T3 true DK1492767T3 (da) 2005-11-28

Family

ID=28791889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03714138T DK1492767T3 (da) 2002-04-01 2003-03-24 Visse 1-(D-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazinforbindelser som inhibitorer af serinproteasefaktoren XA

Country Status (24)

Country Link
US (1) US7166606B2 (enExample)
EP (1) EP1492767B1 (enExample)
JP (1) JP2005531529A (enExample)
KR (1) KR20040094892A (enExample)
CN (1) CN1288135C (enExample)
AT (1) ATE303990T1 (enExample)
AU (1) AU2003218147A1 (enExample)
BR (1) BR0308870A (enExample)
CA (1) CA2478340A1 (enExample)
CR (1) CR7497A (enExample)
DE (1) DE60301569T2 (enExample)
DK (1) DK1492767T3 (enExample)
EA (1) EA007300B1 (enExample)
EC (1) ECSP045329A (enExample)
ES (1) ES2248737T3 (enExample)
HR (1) HRP20040900B1 (enExample)
IL (1) IL164018A0 (enExample)
MX (1) MXPA04009640A (enExample)
NO (1) NO20044688L (enExample)
NZ (1) NZ535402A (enExample)
PL (1) PL373066A1 (enExample)
UA (1) UA76849C2 (enExample)
WO (1) WO2003084929A1 (enExample)
ZA (1) ZA200407418B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6834308B1 (en) 2000-02-17 2004-12-21 Audible Magic Corporation Method and apparatus for identifying media content presented on a media playing device
US7363278B2 (en) 2001-04-05 2008-04-22 Audible Magic Corporation Copyright detection and protection system and method
US8972481B2 (en) 2001-07-20 2015-03-03 Audible Magic, Inc. Playlist generation method and apparatus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2018093716A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
WO1999011657A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. 1-amino-7-isoquinoline derivatives as serine protease inhibitors
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
DE60224805T2 (de) * 2001-07-26 2009-01-22 Eli Lilly And Co., Indianapolis 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine und -piperidine als faktor-xa-antagonisten

Also Published As

Publication number Publication date
US20050096328A1 (en) 2005-05-05
NO20044688L (no) 2004-10-29
BR0308870A (pt) 2005-01-04
WO2003084929A1 (en) 2003-10-16
ZA200407418B (en) 2005-09-15
US7166606B2 (en) 2007-01-23
MXPA04009640A (es) 2005-01-11
EA200401290A1 (ru) 2005-02-24
PL373066A1 (en) 2005-08-08
CR7497A (es) 2005-01-17
ES2248737T3 (es) 2006-03-16
HK1070363A1 (en) 2005-06-17
WO2003084929A8 (en) 2004-05-21
CN1642914A (zh) 2005-07-20
EP1492767A1 (en) 2005-01-05
IL164018A0 (en) 2005-12-18
HRP20040900B1 (en) 2006-02-28
HRP20040900A2 (en) 2004-12-31
KR20040094892A (ko) 2004-11-10
DE60301569D1 (de) 2005-10-13
UA76849C2 (uk) 2006-09-15
EA007300B1 (ru) 2006-08-25
ATE303990T1 (de) 2005-09-15
ECSP045329A (es) 2004-11-26
NZ535402A (en) 2006-02-24
EP1492767B1 (en) 2005-09-07
AU2003218147A1 (en) 2003-10-20
DE60301569T2 (de) 2006-06-14
CN1288135C (zh) 2006-12-06
JP2005531529A (ja) 2005-10-20
CA2478340A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
IS6902A (is) N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl
NO20044995L (no) Heterosykliske forbindelser
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
ATE359271T1 (de) Phenylderivate
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
NO20082629L (no) Macrocyklisk factor VIIa-inhibitorer anvendbare som antikoagulanter
GB0426313D0 (en) Therapeutic agents
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2004031145A3 (en) Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
SE0103710D0 (sv) Compounds
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
DK1492767T3 (da) Visse 1-(D-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazinforbindelser som inhibitorer af serinproteasefaktoren XA
NO20055396D0 (no) Nye fosfonsyreforbindelser som erinproteaseinhibitorer
MY137876A (en) Pharmaceutical compound
NO20064491L (no) Nye difluomtoksysubstituee hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
NO20061302L (no) Derivater av hydroksaminsyre som metalloproteinseinbitorer
DK1637141T3 (da) Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen
HRP20030653B1 (en) Novel benzoylguanidine salt
EA200601086A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE390419T1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-o - derivate als pde4-inhibitoren